Company announcementCompany-reported
What was reported
BURLINGTON, Mass. and JERUSALEM, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of results from a pilot study evaluating the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in patients with co-occurring Major Depressive Disorder (MDD) and early-stage Alzheimer’s disease. The results were published in the peer-reviewed Journal of Geriatric Psychiatry and Neurology.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Sep 8, 2026 · Open the source ↗
What the evidence supports
BrainsWay, a foreign private issuer, furnished a press release to the SEC (Form 6-K) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineBrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Sep 8, 2026 · Open the source ↗
Press release lead paragraphBURLINGTON, Mass. and JERUSALEM, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of results from a pilot study evaluating the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in patients with co-occurring Major Depressive Disorder (MDD) and early-stage Alzheimer’s disease. The results were published in the peer-reviewed Journal of Geriatric Psychiatry and Neurology.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Sep 8, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.